Neurocrine biosciences presents real-world parkinson's disease patient characteristics from ongentys® (opicapone) open-label study at ana2022

San diego , oct. 24, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presented data detailing the baseline characteristics of patients with parkinson's disease (pd) in the opicapone treatment initiation open-label study (opti-on). the poster (poster #m193); parkinson's disease patient characteristics in a u.s. real-world study of opicapone) was presented at the 2022 american neurological association annual meeting (ana2022) being held october 22–25.
NBIX Ratings Summary
NBIX Quant Ranking